methyl 4-(1-(2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate | 1380755-06-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: methyl 4-(1-(2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate
• 英文别名: methyl 4-[1-[[2-[3-[4-fluoro-3-(trifluoromethyl)phenoxy]azetidin-1-yl]-5-(trifluoromethyl)pyridine-3-carbonyl]amino]cyclopropyl]benzoate
• CAS: 1380755-06-5
• 化学式: C₂₈H₂₂F₇N₃O₄
• 分子量: 597.489
• InChiKey: SWNCSDIMJGVEBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  42
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid 、 4-(1-氨基环丙基)-苯甲酸甲酯盐酸盐 生成 methyl 4-(1-(2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate
  参考文献：
  名称：

  PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及式（I）的吡啶酰胺衍生物或其药学上可接受的盐，其中R1和R2独立地是氢、线性或支链（C1-C3）烷基或共同形成环丙基环；R独立地选自卤素和三氟甲基的群体，p为1、2或3；A为C或N；E为式（B）或（C）的基团，其中B为C(O)OH、C(O)O(C1-C3)烷基，C选自式（I），m为1、2或3，n为0或1，W为—O—、—O(C1-C3烷基)-、—(C1-C3烷基)O—、—C(O)—、—C(═N—O(C1-C3烷基))-、—NH—或—NH(C1-C3烷基)-；Ar为苯基，可选地取代一个或多个取代基，所述取代基选自卤素、三氟甲基、三氟甲氧基、甲基、—NH(C1-C3烷基)-、—N(C1-C3烷基)(C1-C3烷基)-、含有一个氮原子的从5到7个成员的杂环环，该氮原子与Ar成共价键，并可选地含有一个或两个选自N、O和S的杂原子；以及含有1至3个选自S、O和N的杂环芳香环，该杂环芳香环被一种或两种取代基所取代，所述取代基选自（C1-C3）烷基、（C3-C5）环烷氧基、（C1-C3）烷基羰基。本发明的化合物可用于制备治疗需要使用EP4受体拮抗剂的病理情况的药物，例如治疗急性和慢性疼痛、炎症性疼痛、骨关节炎、炎症相关疾病如关节炎、类风湿性关节炎、癌症、子宫内膜异位症和偏头痛。

  公开号：

  US20130261100A1

文献信息

• [EN] PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIDINAMIDE EN TANT QU'ANTAGONISTES DE RÉCEPTEUR EP4
  申请人：ROTTAPHARM SPA

  公开号：WO2012076063A1

  公开（公告）日：2012-06-14

  The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is -O-, -O(C1-C3 alkyl)-; -(C1-C3 alkyl)O-; -C(O)-; -C(=N-O(C1-C3 alkyl))-; -NH- or -NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is convalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid artrhritis, cancer, endometriosis and migraine.

  该发明涉及式(I)的吡啶酰胺衍生物或其药学上可接受的盐，其中R1和R2独立地为氢、直链或支链(C1-C3)烷基，或者它们结合在一起形成环丙基环；R独立地选自卤素和三氟甲基的群，p为1、2或3；A为C或N；E为式(B)或(C)的基团，其中B为C(O)OH、C(O)O(C1-C3)烷基，C选自式(I)的群，m为1、2或3，n为0或1，W为-O-、-O(C1-C3烷基)-、-(C1-C3烷基)O-、-C(O)-、-C(=N-O(C1-C3烷基))-、-NH-或-NH(C1-C3烷基)-；Ar为苯基，可选择地取代一个或多个取代基，选自卤素、三氟甲基、三氟甲氧基、甲基、-NH(C1-C3烷基)-、-N(C1-C3烷基)(C1-C3烷基)-，a为含有一个氮原子的5至7元杂环环，与Ar共价键合，可选择地含有一个或两个来自N、O和S的杂原子；以及含有1至3个来自S、O和N的杂原子的5-或6元杂芳环，该杂芳环被选自(C1-C3)烷基、(C3-C5)环烷氧基、(C1-C3)烷基羰基的一或两个取代基取代。该发明的化合物可用于制造用于治疗需要使用EP4受体拮抗剂的病理的药物，例如治疗急性和慢性疼痛、炎症性疼痛、骨关节炎、关节炎、类风湿性关节炎、癌症、子宫内膜异位症和偏头痛。
• Pyridine amide derivatives as EP4 receptor antagonists
  申请人：Borriello Manuela

  公开号：US08828987B2

  公开（公告）日：2014-09-09

  The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is —O—, —O(C1-C3 alkyl)-; —(C1-C3 alkyl)O—; —C(O)—; —C(═N—O(C1-C3 alkyl))-; —NH— or —NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, —NH(C1-C3alkyl)-; —N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, endometriosis and migraine.

  本发明涉及式（I）的吡啶酰胺衍生物或其药学上可接受的盐，其中R1和R2分别独立地为氢、线性或支链（C1-C3）烷基或结合在一起形成环丙基环；R独立地选自卤素和三氟甲基，p为1、2或3；A为C或N；E为式（B）或（C）的基团，其中B为C（O）OH、C（O）O（C1-C3）烷基，C选自式（I），m为1、2或3，n为0或1，W为—O—、—O（C1-C3烷基）-、—（C1-C3烷基）O—、—C（O）—、—C（═N—O（C1-C3烷基））-、—NH—或—NH（C1-C3烷基）-；Ar为苯基，可选地取代一个或多个取代基，所述取代基选自卤素、三氟甲基、三氟甲氧基、甲基、—NH（C1-C3烷基）-、—N（C1-C3烷基）（C1-C3烷基）-、含有一个氮原子的5至7元杂环，该氮原子与Ar共价键合，并可选地含有一或两个选自N、O和S的杂原子；以及含有1至3个选自S、O和N的杂环芳烃环，该杂环芳烃环被一个或两个选自（C1-C3）烷基、（C3-C5）环烷氧基、（C1-C3）烷基羰基的取代基取代。本发明的化合物可用于制造治疗需要使用EP4受体拮抗剂的病理学的药物，例如治疗急性和慢性疼痛、炎症性疼痛、骨关节炎、关节炎、类风湿性关节炎、癌症、子宫内膜异位症和偏头痛等炎症相关疾病。
• US8828987B2
  申请人：——

  公开号：US8828987B2

  公开（公告）日：2014-09-09